This analysis highlights the impact that key sectors have on oral solids and non-sterile liquids drug development.
Since December 2021, the Biden Administration has distributed COVID-19 oral antivirals, including Pfizer’s oral antiviral pill, Paxlovid.1 Although Paxlovid was initially in short supply after Food and Drug Administration (FDA) authorization, there has been accelerated delivery to pharmacies, hospitals, and clinics.
COVID-19 is also impacting the sector economically as the demand for healthcare has increased exponentially around the world as a result of the virus outbreak. For instance, Merck and Ridgeback collaborated on the development of Molnupiravir, an oral antiviral medication. As a result, the oral drug delivery market will reach close to $150 billion by 2027, up from $98 billion in 2020.2
These examples represent how external forces, like politics and the economy, can impact oral solid and non-sterile liquid drug development and delivery. The diagram below highlights how other sectors are influencing these markets.
COVID-19 has had a direct influence on the pharmaceutical industry and changed the way government and private stakeholders reform the healthcare sector, such as placing increasing emphasis on improving and spending GDP. The market is influenced not only by the regulatory framework, but also by non-tariff barriers to trade, such as forced localization, licensing requirements, and protectionism.
According to the IMF World Economic Outlook report, the global economy will reduce from 5.9% in 2021 to 4.9% in 2022. This is attributed to a decrease in both advanced economies (due to supply interruptions) and low-income emerging countries (due to deteriorating pandemic dynamics). However, government expenditure on healthcare remains a high priority.
The rise in the pharma industry will drive the non-sterile liquids market while a rise in chronic diseases will impact the oral solids sector. Apart from this, there is an increased awareness of contract development and manufacturing organizations among pharma players. So taking initiatives to conduct conferences, webinars, etc. is an important strategy so that key voices in the pharma industry can connect with people about both non-sterile liquids and oral solid dosage pharmaceuticals.
Every company has different techniques and strategies for the formulation of APIs, fill-finish products, product development, clinical trials, etc. Key companies carry out collaborations to address key scientific challenges through innovative technologies. Technological improvement will help contract development and manufacturing organizations grow as well as contribute to the world economy.
Companies are designing waste and pollution management strategies to maximize resource efficiency. They are adopting nature-based solutions to protect, sustainably manage, and restore natural and modified ecosystems.
The Food and Drug Administration, the European Union, and the Therapeutic Goods Administration regulate the manufacturing, formulation, testing, etc., of pharmaceutical products. The industry just follow all regulations to gain a solid market share without the risk of regression due to legal standoffs. Contract development and manufacturing organizations will comply with required regulations.